Monica M. Holden

Partner, London

Biography

“Outstanding advisor” Monica Holden according to clients, “has been a real partner to our business over the past several years, advising us through a series of complicated transactions. She is commercial, hardworking, responsive and has taken the time to gain a deep understanding of our business, building connections across our legal, finance and business teams.”
Legal 500, 2020

Overview

Monica Holden is a US qualified partner based in London. She has experience advising on a broad range of global transactions, including mergers and acquisitions, and private and public equity and debt offerings (initial public offerings, private placements and high yield bond transactions) across a number of jurisdictions.

Prior to joining White & Case, Monica worked for an international US law firm where she advised on corporate transactions and public company matters. She also previously practiced as a US certified public accountant with a Big Four firm.

Bars and Courts
Minnesota State Bar
Education
Juris Doctor
University of Minnesota
BA
University of St. Thomas
Languages
English

Experience

Advising Encore Capital Group, Inc. in connection with implementation of its US$1.5 billion global funding structure, including the issuance of €350.0 million in 4.875% senior secured notes due 2025; the consent solicitation of the holders of two existing senior secured notes issuances; the amendment and restatement of Encore's private placement notes purchase agreement; and an amended multi-currency revolving credit facility, with an increased total commitment of US$1.05 billion.

Advising Kobalt Music Group Limited on its agreement to divest its recorded music operations to Sony Music Entertainment.

Advising Takeda in connection with its agreements to divest portfolios of select pharmaceutical assets to:

  • Hasten Biopharmaceutic Co. Ltd. for approximately US$322 million;
  • Cheplapharm for approximately US$562 million;
     
  • Celltrion for up to $278 million;
  • Orifarm Group for approximately $670 million;
  • Hypera Pharma for a total value of US$825 million;
  • STADA Arzneimittel AG for a total value of $660 million; and
  • Acino for a total value in excess of $200 million.

Advising Angelini on its worldwide acquisition, outside North America, of ThermaCare from GlaxoSmithKline (GSK).

Advising the managers, including Bank of America Securities and Deutsche Bank as lead joint bookrunners, in Digital Realty's issuance of three tranches of €1.7 billion in senior unsecured notes.

Advising Amigo Holdings plc on its £369 million IPO and admission to the Premium Listing Segment of the Official List and to trading on the Main Market of the London Stock Exchange.

Advising the initial purchasers in Europcar's simultaneous dual high yield notes offering, including Deutsche Bank, Crédit Agricole CIB and Bank of America Merrill Lynch, as global coordinators and joint bookrunners, on the offering of €600 million 4.125% Senior Notes due 2024 by Europcar Drive D.A.C, and BNP Paribas and HSBC, as global coordinators and joint bookrunners, on the offering of €350 million 2.375% Senior Secured Notes due 2022 by EC Finance plc.

Advising JPMorgan Cazenove and Morgan Stanley, as joint global coordinators, and Deutsche Bank and UBS Investment Bank, as joint bookrunners, in the £405 million IPO of Sophos Group plc admission to the Premium Listing Segment of the Official List and to trading on the Main Market of the London Stock Exchange.

Advising JPMorgan and Credit Suisse, as joint bookrunners, in the US$229 million IPO and listing on Nasdaq of QIWI plc, a leading provider of next generation payment services in Russia and the CIS.